Search
Now showing items 1-10 of 10
Labeling HIV-1 nucleic acids during infection and effect of MOV10 in HBV replication
(University of Missouri--Columbia, 2018)
Technical limitations in simultaneous microscopic visualization of RNA, DNA, and proteins of HIV have curtailed progress in this field. To address this need we have developed a microscopy approach, multiplex immunofluorescent ...
Modulation of HBV infection and replication by cell-derived factors
(University of Missouri--Columbia, 2019)
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT REQUEST OF AUTHOR.] Hepatitis B virus (HBV) infection is one of the most serious health problems. HBV infection leads to serious morbidity and mortality due to the ...
Mechanistic inhibition studies of SARS-CoV replication and entry
(University of Missouri--Columbia, 2012)
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Severe acute respiratory syndrome (SARS) is an infectious and highly contagious disease that is caused by SARS-associated coronavirus, (SARS-CoV) and ...
Probing the viral replication of HCV and XMRV : biochemical characterization, inhibition kinetics and role of host proteins in viral replication
(University of Missouri--Columbia, 2015)
The studies described in this thesis focus on RNA viruses XMRV and HCV. In Chapter II we focused on Xenotropic Murine leukemia-Related Virus (XMRV). We characterized the biochemical activity and kinetics of the XMRV reverse ...
Mechanisms of inhibition and resistance to antiviral drugs targeting human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV)
(University of Missouri--Columbia, 2012)
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Although human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV) are very different viruses, the replication of their genome involves ...
Investigation of antiviral strategies targeting Human Immunodeficiency Virus Type I (HIV-1)
(University of Missouri--Columbia, 2014)
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] HIV-1 infection is currently treated with antiretroviral therapy. Three antiviral approaches were investigated to gain understanding on how HIV-1 can ...
Comparative study of Human Immunodeficiency Virus type 1 and type 2 single and dual infections
(University of Missouri--Columbia, 2020)
Human Immunodeficiency Virus (HIV) type 1 and type 2 are two related lentiviruses that have strikingly divergent features in terms of transmission rates, distribution, pathogenesis, and clinical outcomes. In places where ...
Elucidating the mechanisms and dynamics of drug-mediated inhibition and latency reversal in HIV-1 (HIV-1)
(University of Missouri--Columbia, 2017)
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] The Human Immunodeficiency Virus Type-1 (HIV-1) is the etiological agent of Acquired Immunodeficiency Syndrome, a disease that causes the host to succumb ...
Mechanisms of action and efficacy of HCV direct-acting antiviral agents and the host-targeting agent Cyclosporin A /
(University of Missouri--Columbia, 2016)
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT REQUEST OF AUTHOR.] Hepatitis C virus (HCV) remains a significant public health burden worldwide, with an approximated 170 million people infected globally. Chronic HCV ...
Biochemical characterization of clade B and non-B HIV-1 reverse transcriptase
(University of Missouri--Columbia, 2017)
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT REQUEST OF AUTHOR.] Two classes of drugs: nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs) target HIV-1 RT, an enzyme ...